Structural Analysis of SARS-CoV-2 ORF8 Protein: Pathogenic and Therapeutic Implications.

Current therapeutic strategies and vaccines against SARS-CoV-2 are mainly focused on the Spike protein despite there are other viral proteins with important roles in COVID-19 pathogenicity. For example, ORF8 restructures vesicular trafficking in the host cell, impacts intracellular immunity through the IFN-I signaling, and growth pathways through the mitogen-activated protein kinases (MAPKs). In this mini-review, we analyze the main structural similarities of ORF8 with immunological molecules such as IL-1, contributing to the immunological deregulation observed in COVID-19. We also propose that the blockage of some effector functions of ORF8 with Rapamycin, such as the mTORC1 activation through MAPKs 40 pathway, with Rapamycin, can be a promising approach to reduce COVID-19 mortality.

[Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics]. / Prevalencia de síntomas de ansiedad y de depresión en pacientes con artritis psoriásica en consultas de reumatología.

UNLABELLED: FUNDAMENTAL AND OBJECTIVE: Psychological impairment is frequent in patients with rheumatic diseases. The aim of the study was to assess the prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. PATIENTS AND METHOD: Multicentre cross-sectional study conducted in rheumatology clinics. Patients with psoriatic arthritis were recruited; variables retrieved were sociodemographic, clinical and patient centered (Hospital Anxiety and Depression scale o HADs, EQ-5D questionnaire, etc.). Prevalence in the study population was calculated as anxiety or depression symptoms by an HADs score ≥11 or those receiving pharmacological treatment. A logistics regression model was used to know which variables were related to symptoms of anxiety or depression. RESULTS: A total of 495 patients were included, 42.8% were women and median (SD) age was 50.4 (12.7) years. Prevalence of symptoms of anxiety were 29.7% and prevalence of symptoms of depression was 17,6%. Patients with anxiety or depression symptoms had all EQ-5D dimensions affected (p<0.01). Higher prevalence of anxiety was related to being a woman, a mixed onset pattern with respect to peripheral joints and those treated with DMARD alone with respect to DMARD+NSAID or biologic alone. A higher depression prevalence was related to being a woman and a mixed onset pattern with respect to peripheral joints. CONCLUSION: The prevalence of anxiety symptoms and the prevalence of depression symptoms are high among patients suffering psoriatic arthritis in the studied population.

Prevalencia de síntomas de ansiedad y de depresión en pacientes con artritis psoriásica en consultas de reumatología / Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics

Fundamento y objetivo. Las alteraciones psicológicas son frecuentes entre pacientes con enfermedades reumáticas. El objetivo del estudio fue conocer la prevalencia de los síntomas de ansiedad y depresión en pacientes con artritis psoriásica que acuden a consultas de reumatología. Pacientes y método. Estudio transversal multicéntrico en consultas de reumatología. Se seleccionaron pacientes con artritis psoriásica; se recogieron variables sociodemográficas, clínicas y centradas en el paciente (Escala Hospitalaria de Ansiedad y Depresión o HADs, cuestionario EQ-5D, etc.). Se calculó la prevalencia de síntomas de ansiedad y depresión en esta población según una puntuación ≥11 en HADs o estar recibiendo tratamiento farmacológico. Se utilizó un modelo de regresión logística para conocer las variables relacionadas con la presencia de síntomas de ansiedad o depresión. Resultados. Se incluyeron 495 pacientes, 42,8% mujeres y edad media (DE) de 50,4 (12,7) años. La prevalencia de síntomas de ansiedad fue 29,7% y 17,6% de depresión. Los pacientes con síntomas de ansiedad o depresión presentaron mayor afectación en todas las dimensiones del EQ-5D (p<0,01). La mayor prevalencia en la población de estudio de ansiedad se relacionó con ser mujeres, patrón de debut mixto respecto al periférico y en tratamiento con FAME en monoterapia respecto a FAME+AINES o biológico en monoterapia. La mayor prevalencia de depresión se relacionó con ser mujeres y patrón de debut mixto respecto al periférico. Conclusión. La prevalencia de síntomas de ansiedad y de depresión es elevada en pacientes con artritis psoriásica en la población de este estudio (AU)

Fundamental and Objective. Psychological impairment is frequent in patients with rheumatic diseases. The aim of the study was to assess the prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. Patients and method. Multicentre cross-sectional study conducted in rheumatology clinics. Patients with psoriatic arthritis were recruited; variables retrieved were sociodemographic, clinical and patient centered (Hospital Anxiety and Depression scale o HADs, EQ-5D questionnaire, etc.). Prevalence in the study population was calculated as anxiety or depression symptoms by an HADs score ≥11 or those receiving pharmacological treatment. A logistics regression model was used to know which variables were related to symptoms of anxiety or depression. Results. A total of 495 patients were included, 42.8% were women and median (SD) age was 50.4 (12.7) years. Prevalence of symptoms of anxiety were 29.7% and prevalence of symptoms of depression was 17,6%. Patients with anxiety or depression symptoms had all EQ-5D dimensions affected (p<0.01). Higher prevalence of anxiety was related to being a woman, a mixed onset pattern with respect to peripheral joints and those treated with DMARD alone with respect to DMARD+NSAID or biologic alone. A higher depression prevalence was related to being a woman and a mixed onset pattern with respect to peripheral joints. Conclusion. The prevalence of anxiety symptoms and the prevalence of depression symptoms are high among patients suffering psoriatic arthritis in the studied population (AU)